Skip to Main Content
Skip Nav Destination

The Henipavirus genus in the Paramyxoviridae family currently contains five species; two of those, Hendra virus (HeV) and Nipah virus (NiV), pose a threat to public health. Due to their high case-fatality rate, effective therapeutics are urgently needed. Many compounds have been identified that inhibit HeV and/or NiV replication in vitro. Several of those have also shown efficacy in animal disease models of lethal HeV or NiV infection. In this chapter, we provide a comprehensive overview of the current state of development of antivirals against HeV and NiV with an in-depth discussion of compounds identified in in vitro screens, their mechanism of action, antiviral efficacy data in animal models and where they are in the development pipeline from bench-to-bedside.

You do not currently have access to this chapter, but see below options to check access via your institution or sign in to purchase.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal